Protalix BioTherapeutics (PLX) Misses Q3 EPS by 4c
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Price: $2.40 +0.42%
Revenue Growth %: -49.8%
Financial Fact:
GROSS PROFIT (LOSS): 422K
Today's EPS Names:
CCEL, FNGR, FAST, More
Revenue Growth %: -49.8%
Financial Fact:
GROSS PROFIT (LOSS): 422K
Today's EPS Names:
CCEL, FNGR, FAST, More
Join SI Premium – FREE
Protalix BioTherapeutics (NYSE: PLX) reported Q3 EPS of $0.03, $0.04 worse than the analyst estimate of $0.07. Revenue for the quarter came in at $17.67 million versus the consensus estimate of $17.79 million.
For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- NVIDIA, Mitsubishi Heavy Industries eye cooperation on AI data center cooling and power - Nikkei
- Manpower Inc. (MAN) PT Raised to $41 at UBS Ahead of Q2 Earnings
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
